DTIL (Precision BioSciences) Quality Rank


DTIL Precision BioSciences Inc DTIL
50 GF Score
Price $8.77
GF Value $1.83
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Precision BioSciences Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Precision BioSciences Quality Rank Related Terms

DTIL
50GF Score
Precision BioSciences Inc DTIL
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Precision BioSciences (DTIL) Overvalued in 2026?

Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued. The current stock price of $8.77 is trading 379% above its estimated GF Value™ of $1.83. GuruFocus considers Precision BioSciences to be Significantly Overvalued.

Key valuation signals for DTIL:

  • Quality Rank:
  • GF Value™: $1.83 vs. price of $8.77 (379% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precision BioSciences Business Description

Other Exchanges PBS0:Germany
Address 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
50GF Score

Get the complete analysis for DTIL

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.77
Price
$1.83
GF Value